NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Overall MarketRank^™

1.13 out of 5 stars

Medical Sector

988th out of 2,042 stocks

Biological Products, Except Diagnostic Industry

126th out of 177 stocks

1.5 Analyst's Opinion

Consensus Rating
NantKwest has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.00, NantKwest has a forecasted upside of 7.5% from its current price of $16.74.
Amount of Analyst Coverage
NantKwest has received no research coverage in the past 90 days.

2.5 Community Rank

Outperform Votes
NantKwest has received 273 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
NantKwest has received 266 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
NantKwest has received 50.65% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about NantKwest and other stocks. Vote “Outperform” if you believe NK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
NantKwest does not currently pay a dividend.
Dividend Growth
NantKwest does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NantKwest insiders have not sold or bought any company stock.
Percentage Held by Insiders
71.73% of the stock of NantKwest is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 9.38% of the stock of NantKwest is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for NantKwest are expected to decrease in the coming year, from ($0.77) to ($0.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NantKwest is -23.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NantKwest is -23.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NantKwest has a P/B Ratio of 13.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

NantKwest (NASDAQ:NK) Frequently Asked Questions

Is NantKwest a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NantKwest in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NantKwest stock.
View analyst ratings for NantKwest or view top-rated stocks.

What stocks does MarketBeat like better than NantKwest?

Wall Street analysts have given NantKwest a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NantKwest wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were NantKwest's earnings last quarter?

NantKwest, Inc. (NASDAQ:NK) announced its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. NantKwest had a negative trailing twelve-month return on equity of 56.06% and a negative net margin of 76,658.58%.
View NantKwest's earnings history.

What price target have analysts set for NK?

1 analysts have issued twelve-month target prices for NantKwest's shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate NantKwest's share price to reach $18.00 in the next year. This suggests a possible upside of 7.5% from the stock's current price.
View analysts' price targets for NantKwest or view top-rated stocks among Wall Street analysts.

Who are NantKwest's key executives?

NantKwest's management team includes the following people:

Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 56, Pay $454.44k)
Ms. Sonja Nelson, Chief Financial Officer (Age 48, Pay $442.69k)
Mr. Richard Gerald Adcock, Chief Exec. Officer (Age 52)
Mr. Steven Yang J.D., VP, Gen. Counsel & Corp. Sec.
Dr. Jerel A. Banks Ph.D., M.D., Sr. VP Mergers and Acquisitions (Age 46)
Mr. Leonard S. Sender, Sr. VP of Medical Affairs - Pediatric, Adolescent & Young Adult Oncology
Dr. Hans Georg Klingemann, VP of R&D (Age 71)

What is Dr. Patrick Soon-Shiong's approval rating as NantKwest's CEO?

14 employees have rated NantKwest CEO Dr. Patrick Soon-Shiong on Glassdoor.com. Dr. Patrick Soon-Shiong has an approval rating of 55% among NantKwest's employees. This puts Dr. Patrick Soon-Shiong in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of NantKwest's key competitors?

Some companies that are related to NantKwest include Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Vir Biotechnology (VIR), Kodiak Sciences (KOD), Adaptive Biotechnologies (ADPT), China Biologic Products (CBPO), Beam Therapeutics (BEAM), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Ablynx (ABLYF), SpringWorks Therapeutics (SWTX) and NanoString Technologies (NSTG).
View all of NK's competitors.

What other stocks do shareholders of NantKwest own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NantKwest investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN) and ADMA Biologics (ADMA).

When did NantKwest IPO?

(NK) raised $150 million in an initial public offering on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

What is NantKwest's stock symbol?

NantKwest trades on the NASDAQ under the ticker symbol "NK."

Who are NantKwest's major shareholders?

NantKwest's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Strategic Wealth Management Group LLC (0.01%). Company insiders that own NantKwest stock include Barry J Simon, Frederick W Driscoll, John C Thomas, Patrick Soon-Shiong and Sonja Nelson.
View institutional ownership trends for NantKwest.

Which institutional investors are buying NantKwest stock?

NK stock was bought by a variety of institutional investors in the last quarter, including Strategic Wealth Management Group LLC.
View insider buying and selling activity for NantKwest or or view top insider-buying stocks.

What is NantKwest's stock price today?

One share of NK stock can currently be purchased for approximately $16.74.

How much money does NantKwest make?

NantKwest has a market capitalization of $1.83 billion and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does NantKwest have?

NantKwest employs 160 workers across the globe.

What is NantKwest's official website?

The official website for NantKwest is www.nantkwest.com.

Where are NantKwest's headquarters?

NantKwest is headquartered at 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121.

How can I contact NantKwest?

NantKwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]

This page was last updated on 5/9/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

NantKwest Stock Forecast, Price & News

Adding

Adding

Adding NantKwest, Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Headlines

About NantKwest

MarketRank™

Overall MarketRank™